Sara Miqueleiz

Hospital de Sant Pau

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Enrica Morra

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Francesca Ricci

Humanitas University

Alessandra Tedeschi

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Marco Montillo

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Clara Cesana

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Marzia Varettoni

Policlinico San Matteo Fondazione

Mario Lazzarino

ASST Fatebenefratelli Sacco

Barbara Scarpati

Ospedale Antonio Cardarelli

Eleonora Vismara

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Luciana Barbarano

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Cooperative Institutions

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Istituti di Ricovero e Cura a Carattere Scientifico

Ospedale Maggiore

University of Pavia

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

University of Milan

Hospital de Sant Pau

Policlinico San Matteo Fondazione

Azienda Socio Sanitaria Territoriale Lariana

University of Parma

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis

Haematologica (2022)

José Manuel Soria Sergi Mojal Ángel Martínez-Pérez Francisco René Acosta Sònia López

Not available.

2019-20 coronavirus outbreak

10.3324/haematol.2022.281068

Cite

Citations (1)

Smouldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic disease

Seminars in Oncology (2003)

Clara Cesana Sara Miqueleiz Patrizia Bernuzzi Elisabetta Tresoldi Valentina Rossi

Macroglobulinemia

10.1053/sonc.2003.50056

Cite

Citations (22)

Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.

Blood (2009)

Marzia Varettoni Alessandra Tedeschi Cristiana Pascutto Eleonora Vismara Luca Arcaini

Macroglobulinemia

10.1182/blood.v114.22.3951.3951

Cite

Citations (1)

Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.

Blood (2007)

Ester Pungolino Silvia Cantoni Cecilia Del Curto Livio Gargantini Marianna Caramella

Imatinib Mesylate

10.1182/blood.v110.11.4577.4577

Cite

Citations (1)

Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19

Journal of Thrombosis and Thrombolysis (2021)

Mariana Corrochano René Acosta-Isaac Sergi Mojal Sara Miqueleiz Diana Rodríguez

Anticoagulant therapy is a cornerstone treatment for coronavirus disease 2019 (COVID-19) due to the high rates of thromboembolic complications associated with this disease. We hypothesized that chronic antithrombotic therapy could play a protective role in patients hospitalized for COVID-19. Retrospective, observational study of all patients admitted to our hospital for ≥ 24 h from March 1 to May 31, 2020 with SARS-CoV-2. The objective was to evaluate clinical outcomes and mortality in COVID-19 patients receiving chronic anticoagulation (AC) or antiplatelet therapy (AP) prior to hospital admission. A total of 1612 patients were evaluated. The mean (standard deviation; SD) age was 66.5 (17.1) years. Patients were divided into three groups according to the use of antithrombotic therapy prior to admission (AP, AC, or no-antithrombotic treatment). At admission, 9.6% of the patients were taking anticoagulants and 19.1% antiplatelet therapy. The overall mortality rate was 19.3%. On the multivariate analysis there were no significant differences in mortality between the antithrombotic groups (AC or AP) and the no-antithrombotic group (control group). Patients on AC had lower ICU admission rates than the control group (OR: 0.41, 95% CI, 0.18–0.93). Anticoagulation therapy prior to hospitalization for COVID-19 was associated with lower ICU admission rates. However, there were no significant differences in mortality between the patients receiving chronic antithrombotic therapy and patients not taking antithrombotic medications. These findings suggest that chronic anticoagulation therapy at the time of COVID-19 infection may reduce disease severity and thus the need for ICU admission.

10.1007/s11239-021-02507-2

Cite

Citations (19)

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Blood (2007)

Marco Montillo Sara Miqueleiz Alessandra Tedeschi Francesca Ricci Eleonora Vismara

Minimal Residual Disease

Regimen

10.1182/blood.v110.11.3133.3133

Cite

Citations (11)

Prognostic Factors for Transformation in Asymptomatic Immunoglobulin M Monoclonal Gammopathies